{"id":"https://openalex.org/W4243095254","doi":"https://doi.org/10.1182/blood.v114.22.883.883","title":"An Ongoing Phase 1/2a Study of ABT-263; Pharmacokinetics (PK), Safety and Anti-Tumor Activity in Patients (pts) with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL).","display_name":"An Ongoing Phase 1/2a Study of ABT-263; Pharmacokinetics (PK), Safety and Anti-Tumor Activity in Patients (pts) with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL).","publication_year":2009,"publication_date":"2009-11-20","ids":{"openalex":"https://openalex.org/W4243095254","doi":"https://doi.org/10.1182/blood.v114.22.883.883"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v114.22.883.883","doi":"https://doi.org/10.1182/blood.v114.22.883.883","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v114.22.883.883","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5033407869","display_name":"Andrew Warwick Roberts","orcid":"https://orcid.org/0000-0002-7341-5720","observed_orcids":["https://orcid.org/0000-0002-7341-5720","https://orcid.org/0000-0001-5347-7169"]},"institutions":[{"id":"https://openalex.org/I196021976","display_name":"Walter and Eliza Hall Institute of Medical Research","ror":"https://ror.org/01b6kha49","country_code":"AU","type":"nonprofit","lineage":["https://openalex.org/I196021976"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Andrew W. Roberts","raw_affiliation_strings":["Div. of Cancer and Haem., The Walter & Eliza Hall Institute of Medical Research, Parkville, Australia,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Div. of Cancer and Haem., The Walter & Eliza Hall Institute of Medical Research, Parkville, Australia,","institution_ids":["https://openalex.org/I196021976"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081326206","display_name":"John Francis Seymour","orcid":"https://orcid.org/0000-0003-2188-6835","observed_orcids":["https://orcid.org/0000-0003-2188-6835"]},"institutions":[{"id":"https://openalex.org/I2800555584","display_name":"Peter MacCallum Cancer Centre","ror":"https://ror.org/02a8bt934","country_code":"AU","type":"healthcare","lineage":["https://openalex.org/I2800555584"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"John F Seymour","raw_affiliation_strings":["Dept of Haematology, Peter MacCallum Cancer Institute, Victoria, Australia,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dept of Haematology, Peter MacCallum Cancer Institute, Victoria, Australia,","institution_ids":["https://openalex.org/I2800555584"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016570475","display_name":"Jennifer R. Brown","orcid":"https://orcid.org/0000-0003-2040-4961","observed_orcids":["https://orcid.org/0000-0003-2040-4961"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jennifer R Brown","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA, USA,","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089428686","display_name":"William G. Wierda","orcid":"https://orcid.org/0000-0002-7357-270X","observed_orcids":["https://orcid.org/0000-0002-7357-270X"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"William G Wierda","raw_affiliation_strings":["M.D. Anderson Cancer Center, The University of Texas, Houston, TX, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"M.D. Anderson Cancer Center, The University of Texas, Houston, TX, USA,","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036828560","display_name":"Thomas J. Kipps","orcid":"https://orcid.org/0000-0002-0064-4549","observed_orcids":["https://orcid.org/0000-0002-0064-4549"]},"institutions":[{"id":"https://openalex.org/I36258959","display_name":"University of California San Diego","ror":"https://ror.org/0168r3w48","country_code":"US","type":"education","lineage":["https://openalex.org/I36258959"]},{"id":"https://openalex.org/I4390039236","display_name":"Moores Cancer Center","ror":"https://ror.org/01qkmtm61","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2800935791","https://openalex.org/I36258959","https://openalex.org/I4390039236"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Thomas J. Kipps","raw_affiliation_strings":["Moores UCSD Cancer Center, CLL Research Consortium, La Jolla, CA, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Moores UCSD Cancer Center, CLL Research Consortium, La Jolla, CA, USA,","institution_ids":["https://openalex.org/I36258959","https://openalex.org/I4390039236"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007604802","display_name":"Dennis A. Carney","orcid":"https://orcid.org/0000-0003-3239-6065","observed_orcids":["https://orcid.org/0000-0003-3239-6065"]},"institutions":[{"id":"https://openalex.org/I2800555584","display_name":"Peter MacCallum Cancer Centre","ror":"https://ror.org/02a8bt934","country_code":"AU","type":"healthcare","lineage":["https://openalex.org/I2800555584"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Dennis Carney","raw_affiliation_strings":["Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia,","institution_ids":["https://openalex.org/I2800555584"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016906085","display_name":"Hao Xiong","orcid":"https://orcid.org/0000-0001-6222-426X","observed_orcids":["https://orcid.org/0000-0001-6222-426X"]},"institutions":[{"id":"https://openalex.org/I4210088555","display_name":"Abbott (United States)","ror":"https://ror.org/0052svj16","country_code":"US","type":"company","lineage":["https://openalex.org/I4210088555"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Hao Xiong","raw_affiliation_strings":["Abbott Laboratories, Abbott Park, IL,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Abbott Laboratories, Abbott Park, IL,","institution_ids":["https://openalex.org/I4210088555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032087142","display_name":"Yue Cui","orcid":"https://orcid.org/0000-0003-1882-5441","observed_orcids":["https://orcid.org/0000-0003-1882-5441"]},"institutions":[{"id":"https://openalex.org/I4210088555","display_name":"Abbott (United States)","ror":"https://ror.org/0052svj16","country_code":"US","type":"company","lineage":["https://openalex.org/I4210088555"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Yue Cui","raw_affiliation_strings":["Abbott Laboratories, Abbott Park, IL,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Abbott Laboratories, Abbott Park, IL,","institution_ids":["https://openalex.org/I4210088555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112254057","display_name":"Todd A. Busman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210088555","display_name":"Abbott (United States)","ror":"https://ror.org/0052svj16","country_code":"US","type":"company","lineage":["https://openalex.org/I4210088555"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Todd Busman","raw_affiliation_strings":["Abbott Laboratories, Abbott Park, IL,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Abbott Laboratories, Abbott Park, IL,","institution_ids":["https://openalex.org/I4210088555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030362067","display_name":"Sari Heitner Enschede","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210088555","display_name":"Abbott (United States)","ror":"https://ror.org/0052svj16","country_code":"US","type":"company","lineage":["https://openalex.org/I4210088555"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Sari Enschede","raw_affiliation_strings":["Abbott Laboratories, Abbott Park, IL,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Abbott Laboratories, Abbott Park, IL,","institution_ids":["https://openalex.org/I4210088555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076368703","display_name":"Andrew Krivoshik","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210088555","display_name":"Abbott (United States)","ror":"https://ror.org/0052svj16","country_code":"US","type":"company","lineage":["https://openalex.org/I4210088555"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Andrew Krivoshik","raw_affiliation_strings":["Abbott Laboratories, Abbott Park, IL, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Abbott Laboratories, Abbott Park, IL, USA","institution_ids":["https://openalex.org/I4210088555"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5059315880","display_name":"Rod A. Humerickhouse","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210088555","display_name":"Abbott (United States)","ror":"https://ror.org/0052svj16","country_code":"US","type":"company","lineage":["https://openalex.org/I4210088555"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Rod Humerickhouse","raw_affiliation_strings":["Abbott Laboratories, Abbott Park, IL,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Abbott Laboratories, Abbott Park, IL,","institution_ids":["https://openalex.org/I4210088555"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":7,"corresponding_author_ids":["https://openalex.org/A5016906085","https://openalex.org/A5030362067","https://openalex.org/A5032087142","https://openalex.org/A5059315880","https://openalex.org/A5076368703","https://openalex.org/A5089428686","https://openalex.org/A5112254057"],"corresponding_institution_ids":["https://openalex.org/I1343551460","https://openalex.org/I4210088555"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":2.1141,"has_fulltext":false,"cited_by_count":16,"citation_normalized_percentile":{"value":0.87320681,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":97},"biblio":{"volume":"114","issue":"22","first_page":"883","last_page":"883"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10294","display_name":"Cell death mechanisms and regulation","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/navitoclax","display_name":"navitoclax","score":0.9909999966621399},{"id":"https://openalex.org/keywords/venetoclax","display_name":"venetoclax","score":0.9459999799728394},{"id":"https://openalex.org/keywords/bcl2-inhibitors","display_name":"BCL-2 inhibitor","score":0.6819999814033508},{"id":"https://openalex.org/keywords/bh3-mimetics","display_name":"BH3 mimetics","score":0.949999988079071},{"id":"https://openalex.org/keywords/relapsed-refractory-chronic-lymphocytic-leukemia","display_name":"relapsed/refractory chronic lymphocytic leukemia","score":0.9470000267028809},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8270000219345093},{"id":"https://openalex.org/keywords/thrombocytopenia","display_name":"thrombocytopenia","score":0.8529999852180481},{"id":"https://openalex.org/keywords/platelet-nadir","display_name":"platelet nadir","score":0.8109999895095825},{"id":"https://openalex.org/keywords/dosing-regimen","display_name":"dosing regimen","score":0.7730000019073486},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.5379999876022339},{"id":"https://openalex.org/keywords/bcl-xl","display_name":"Bcl-xL","score":0.5690000057220459}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7263592481613159},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.6635275483131409},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.5760550498962402},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5200985670089722},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.45454996824264526},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.4208187758922577},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.41051509976387024},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.32773324847221375},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.10069328546524048},{"id":"https://openalex.org/C87355193","wikidata":"https://www.wikidata.org/wiki/Q411","display_name":"Astrobiology","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v114.22.883.883","doi":"https://doi.org/10.1182/blood.v114.22.883.883","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v114.22.883.883","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2561192604","https://openalex.org/W2584707798","https://openalex.org/W2547375761","https://openalex.org/W2537096782","https://openalex.org/W2257961914","https://openalex.org/W2240679114","https://openalex.org/W2569264158","https://openalex.org/W2243608423","https://openalex.org/W2537798135","https://openalex.org/W2070557475"],"abstract_inverted_index":{"Abstract":[0,1],"883":[2],"ABT-263,":[3],"a":[4,72,78,117,138,168,172,191,319],"novel":[5],"orally":[6],"bioavailable":[7],"BH3":[8],"mimetic,":[9],"binds":[10],"with":[11,97,120,163,190,230,331,363],"high":[12],"affinity":[13],"(Ki":[14],"\u2264":[15,31],"1nM)":[16],"and":[17,40,55,66,88,223,247,257,264,271,282,301,304,314,352,402,426,460,471,475,490],"inhibits":[18],"multiple":[19],"antiapoptotic":[20],"Bcl-2":[21,34,65],"family":[22],"proteins.":[23],"In":[24],"vitro,":[25],"ABT-263":[26,85,183,468,535],"potently":[27],"induces":[28],"apoptosis":[29,550],"(EC50":[30],"1\u03bcM)":[32],"in":[33,52,95,226,322,349,411,551],"overexpressing":[35],"human":[36],"lymphoma":[37],"cell":[38],"lines":[39],"primary":[41],"CLL":[42],"cells.":[43],"Preclinical":[44],"mechanism-based":[45],"toxicities":[46,407],"include":[47],"inhibition":[48,62],"of":[49,58,63,91,116,128,176,182,194,267],"spermatogenesis,":[50],"reduction":[51],"circulating":[53,59,323],"lymphocytes":[54],"decreased":[56],"survival":[57],"platelets,":[60],"reflecting":[61],"Bcl-w,":[64],"Bcl-XL,":[67],"respectively.":[68],"Study":[69],"M06-873":[70],"is":[71,376,512,536,541,546],"phase":[73,509],"1/2a":[74],"dose-escalation":[75],"trial":[76],"employing":[77],"continuous":[79,147,485,497,521],"reassessment":[80],"method":[81],"(CRM)":[82],"to":[83,132,151,209,360,548],"evaluate":[84],"PK,":[86],"safety":[87,477],"antitumor":[89],"activity":[90],"two":[92],"dosing":[93,149,217,486,498],"schedules":[94],"pts":[96,165,317,333,351,354,413,437,443],"relapsed":[98],"or":[99],"refractory":[100],"CLL.":[101],"Tumor":[102],"responses":[103,299],"were":[104,111,199,390,409],"evaluated":[105],"by":[106,146,205,241,336,484,518],"the":[107,126,219,261,286,290,339,364,371,415,435,439,495,500],"NCI-WG":[108],"criteria.":[109],"Pts":[110],"initially":[112],"dosed":[113],"on":[114,167,171,202,374,414,438,494],"d1-14":[115],"21d":[118],"cycle":[119,239,491],"10-250":[121],"mg":[122,140,162,189,259,281,284,430,449,456,464,514],"ABT-263.":[123],"To":[124],"ameliorate":[125],"impact":[127],"thrombocytopenia":[129,399],"(TCP)":[130],"due":[131,208],"on-target":[133],"Bcl-XL":[134],"inhibition-induced":[135],"platelet":[136,221,227,234,488],"apoptosis,":[137],"100":[139,513],"lead-in":[141,482,516],"dose":[142,511],"for":[143,260,285,327,504],"7d":[144],"followed":[145,204,483,517],"21/21d":[148,173,287,440,496],"(up":[150],"300mg/d)":[152],"was":[153,184,343,347,469],"investigated.":[154],"This":[155],"study":[156,375],"has":[157],"completed":[158],"enrollment":[159],"at":[160,251,275,419,428,447,454,462],"300":[161,283,463],"29":[164],"(15":[166],"14/21d;":[169],"14":[170,436],"schedule)":[174],"as":[175,307],"June":[177],"2009.":[178],"The":[179,384,507],"PK":[180,474],"exposure":[181],"approximately":[185],"dose-proportional":[186],"from":[187,249,273],"10-300":[188],"terminal":[192],"half-life":[193],"11":[195],"h.":[196],"Platelet":[197],"nadirs":[198],"transient,":[200],"occurring":[201],"d3-5":[203],"partial":[206,298],"recovery":[207],"compensatory":[210],"increased":[211],"megakaryopoiesis":[212],"during":[213,238],"continued":[214],"dosing.":[215,232,522],"Lead-in":[216],"reduced":[218],"early":[220],"nadir,":[222],"minimized":[224],"fluctuations":[225],"count":[228,235,326],"observed":[229,410],"intermittent":[231],"Circulating":[233],"dropped":[236],"maximally":[237],"1":[240,427,446,453,461],"an":[242,265,537],"average":[243,266],"12%,":[244],"57%,":[245],"68%":[246,272],"70%":[248],"baseline":[250,274],"10":[252],"mg,":[253,255,277,279],"110":[254],"200":[256,278,448],"250":[258,280,429,455,519],"14/21d":[262,416],"schedule,":[263,441],"52%,":[268],"63%,":[269],"63%":[270],"125":[276],"schedule.":[288],"Of":[289],"21":[291],"evaluable":[292],"pts,":[293],"2":[294,329,332,353,418,458,510],"had":[295,306,355,472],"radiographically":[296],"confirmed":[297],"(99%":[300],"79%":[302],"reductions)":[303],"3":[305,412,442],"yet":[308,368,543],"unconfirmed":[309],"nodal":[310],"regression":[311],"(100%,":[312],"71%":[313],"55%).":[315],"7":[316],"maintained":[318],"\u226550%":[320],"decrease":[321],"absolute":[324],"lymphocyte":[325],"\u2265":[328],"months":[330],"having":[334],"PR":[335],"physical":[337],"examination;":[338],"overall":[340],"response":[341],"rate":[342],"33%.":[344],"Stable":[345],"disease":[346],"noted":[348],"8":[350],"progressive":[356],"disease.":[357],"Responses":[358],"tend":[359],"be":[361],"durable,":[362],"median":[365,372],"PFS":[366],"not":[367,542],"reached":[369],"while":[370],"time":[373],"9":[377],"mos":[378],"(range":[379],"0.63":[380],"-":[381],"18.4":[382],"mos).":[383],"most":[385],"common":[386],"adverse":[387],"events":[388],"(AE)":[389],"diarrhea":[391],"(52%),":[392],"nausea":[393],"(44%),":[394],"vomiting":[395],"(24%),":[396],"fatigue":[397],"(24%)":[398],"(TCP;":[400],"20%)":[401],"neutropenia":[403],"(12%).":[404],"Dose":[405],"limiting":[406],"(DLT)":[408],"schedule;":[417],"110mg":[420],"(hospitalization":[421],"&":[422],"Grade":[423],"4":[424,432,451,466],"TCP)":[425],"(Grade":[431,450,457,465],"TCP).":[433,467],"Among":[434],"experienced":[444],"DLT;":[445],"TCP);":[452],"nausea)":[459],"well-tolerated":[470],"favorable":[473],"acceptable":[476],"profiles.":[478],"One":[479],"week":[480],"100mg/d":[481],"minimizes":[487],"nadir":[489],"variability.":[492],"Based":[493],"data,":[499],"CRM":[501],"model":[502],"projection":[503],"MTD":[505],"converged.":[506],"recommended":[508],"7-d":[515],"mg/d":[520],"Disclosures:":[523],"Roberts:":[524],"Abbott":[525],":":[526],"Research":[527,530,555,558,580],"Funding;":[528,556,581],"Genentech:":[529,564],"Funding.":[531,559],"Off":[532],"Label":[533],"Use:":[534],"experimental":[538],"drug":[539],"that":[540],"registered.":[544],"It":[545],"designed":[547],"induce":[549],"tumor":[552],"cells..":[553],"Brown:Celgene:":[554],"Genzyme:":[557],"Wierda:GSK:":[560],"Consultancy;":[561,563,565,567,569,571],"Ligand:":[562],"MEDIMMUNE:":[566],"ABBOTT:":[568],"TRUBION:":[570],"BAYER,":[572],"SANOFI-AVENTIS,":[573],"MEMGEN,":[574],"GENITOPE,":[575],"GENMAB,":[576],"SUNESIS,":[577],"ABBOTT,":[578],"GSK:":[579],"GENENTECH:":[582],"Honoraria;":[583],"CELGENE:":[584],"Speakers":[585],"Bureau.":[586],"Xiong:Abbott:":[587],"Employment.":[588,590,592,594,596,598],"Cui:Abbott:":[589],"Busman:Abbott:":[591],"Enschede:Abbott:":[593],"Krivoshik:Abbott:":[595],"Humerickhouse:Abbott:":[597]},"counts_by_year":[{"year":2015,"cited_by_count":1},{"year":2013,"cited_by_count":1},{"year":2012,"cited_by_count":3}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2022-05-12T00:00:00"}